Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Update on General Meeting

8 Feb 2022 09:34

RNS Number : 0204B
Sensyne Health PLC
08 February 2022
 

 

 

Sensyne Health plc

("Sensyne" or the "Company")

 

Update on General Meeting

 

Confirmed cases of COVID-19 mean that General Meeting will be held as a closed meeting

 

Oxford, U.K. 8 February 2022: Sensyne Health plc (LSE:SENS) today announces that due to a number of confirmed COVID-19 cases, the Company's General Meeting to be held at 2.00 p.m. on Friday, 11 February 2022 (the "General Meeting") will now be held as a closed meeting, with the minimum number of members legally required to be present to form a quorum in accordance with the Company's articles of association. Shareholders will not be permitted to attend in person and are therefore advised not to travel to the General Meeting. The Company is taking these precautionary measures to safeguard its shareholders', stakeholders' and employees' health and make the General Meeting as safe and efficient as possible.

 

Shareholders are encouraged to submit their votes by proxy in advance and to appoint the Chair of the meeting as their proxy (rather than their own choice of person), with voting instructions, to ensure their vote is counted. Completed forms of proxy must be returned so as to be received by the Company's Registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA by no later than 2.00 p.m. on 9 February 2022, as set out in the Notice of General Meeting contained within the Circular sent to shareholders on 26 January 2022. The Circular is available from the Company's website at https://www.sensynehealth.com/investors/shareholder-information. Shareholders' attention is again drawn to the importance of voting at the General Meeting.

 

A video link for virtual attendance is being made available to provide shareholders with the opportunity to listen to the General Meeting and to have their questions answered. If you would like to join the video conference, please contact CSCSensynehealth@consilium-comms.com by close of business on Wednesday, 9 February 2022.

 

 

 

-ENDS-

Notes for editors:

About Sensyne Health: https://www.sensynehealth.com/

Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organisations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

Contact details:

Sensyne Health

 

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Dr Richard Pye, Chief Financial Officer

+44 (0) 330 058 1845

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7418 8900

 

Dr Christopher Golden

James Steel

 

 

Liberum (Joint Broker)

Phil Walker

William Hall

+ 44 (0) 20 3100 2000

Consilium Strategic Communications

Mary-Jane Elliott

Jessica Hodgson

CSCSensynehealth@consilium-comms.com

+44 (0) 7780 600290

SternIR

Julie Seidel

Julie.seidel@sternir.com

 +1 (212) 362 1200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGFIFVAFLITIIF
Date   Source Headline
19th Aug 20202:00 pmRNSPrice Monitoring Extension
19th Aug 20207:00 amRNSDevelopment of ‘DBm-Health™’ for diabetes
17th Aug 20204:41 pmRNSSecond Price Monitoring Extn
17th Aug 20204:36 pmRNSPrice Monitoring Extension
13th Aug 20202:06 pmRNSSecond Price Monitoring Extn
13th Aug 20202:00 pmRNSPrice Monitoring Extension
10th Aug 20207:00 amRNSSensyne Health settles employment tribunal claim
20th May 202011:05 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
19th May 20204:00 pmRNSLaunch of CVm-Health app in the US
14th May 20207:00 amRNSTrading and Business Update
5th May 20207:00 amRNSSensyne Health launches BPm-Health product
20th Apr 20207:00 amRNSLaunch of CVm-Health ‘Good Neighbour’ app
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:37 pmRNSPrice Monitoring Extension
30th Mar 20202:05 pmRNSSecond Price Monitoring Extn
30th Mar 20202:00 pmRNSPrice Monitoring Extension
27th Mar 20204:42 pmRNSSecond Price Monitoring Extn
27th Mar 20204:37 pmRNSPrice Monitoring Extension
27th Mar 20202:52 pmRNSGDm-Health free to NHS in response to COVID-19
11th Mar 20209:00 amRNSHolding(s) in Company
2nd Mar 20205:29 pmRNSInterim Chief Financial Officer appointment
2nd Mar 20208:18 amRNSDirectorate Change
28th Feb 20204:00 pmRNSHSJ Partnership Award for GDm-Health
3rd Feb 20207:00 amRNSHoldings in Company
21st Jan 20207:00 amRNSSensyne Health confirms benefits in study
21st Jan 20207:00 amRNSSensyne Health Interim Results
16th Jan 20202:05 pmRNSSecond Price Monitoring Extn
16th Jan 20202:00 pmRNSPrice Monitoring Extension
23rd Dec 20197:00 amRNSSensyne Health enters AI research collaboration
20th Dec 20199:00 amRNSNotice of Results
16th Dec 20197:00 amRNSUpdate Following General Election
10th Dec 20197:00 amRNSBoard Changes
15th Nov 20197:00 amRNSCognizant and Agorai named as partners
30th Oct 20192:28 pmRNSResult of AGM
30th Oct 20197:41 amRNSDirectorate Change
22nd Oct 20197:00 amRNSAppointment of Joint Broker and Financial Adviser
22nd Oct 20197:00 amRNSRemuneration Policy and Corporate Governance
17th Oct 20195:21 pmRNSHolding(s) in Company
15th Oct 20195:16 pmRNSHolding(s) in Company
10th Oct 20197:00 amRNSSensyne extends partnership with Bayer
7th Oct 20197:00 amRNSAnnual Report and Accounts
7th Oct 20197:00 amRNSCollaboration with UK MHRA
7th Oct 20197:00 amRNSMajor Agreements for digital health products in US
7th Oct 20197:00 amRNSSensyne Health Maiden Full Year Results
4th Oct 20197:00 amRNSBoard Change
4th Oct 20197:00 amRNSRelated party transactions
23rd Sep 201912:00 pmRNSBoard Change
12th Sep 20197:00 amRNSNotice of Full Year Results
2nd Aug 201912:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.